PTCT — PTC Therapeutics Share Price
0.000.00%
Last trade - 00:00- $3.88bn
- $4.29bn
- $806.78m
- 72
- 96
- 90
- 98
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 40.46 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -63.13% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 5.56 | ||
| Price to Sales | 2.2 | ||
| EV to EBITDA | 5.07 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 40.78% | ||
| Return on Equity | n/a | ||
| Operating Margin | 46.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 380.77 | 538.59 | 698.8 | 937.82 | 806.78 | 1,742.46 | 899.79 | 21.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Directors
- Michael Schmertzler NEC (69)
- Stuart Peltz CEO (61)
- Emily Hill CFO (41)
- Neil Almstead COO (54)
- Matthew Klein COO (50)
- Mark Boulding EVP (60)
- Christine Utter SVP (43)
- Eric Pauwels OTH (60)
- Allan Jacobson IND (75)
- Stephanie Okey IND (61)
- Emma Reeve IND (60)
- Mary Smith IND (58)
- David Southwell IND (60)
- Glenn Steele IND (75)
- Dawn Svoronos IND (67)
- Jerome Zeldis IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- March 31st, 1998
- Public Since
- June 20th, 2013
- No. of Shareholders
- 78
- No. of Employees
- 939
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 79,438,094
- Address
- 500 Warren Corporate Center Drive, WARREN, 07059
- Web
- https://www.ptcbio.com/
- Phone
- +1 9082227000
- Auditors
- Ernst & Young LLP
Upcoming Events for PTCT
Similar to PTCT
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the PTC Therapeutics share price?
As of Today at 22:46 UTC, shares in PTC Therapeutics are trading at $48.82. This share price information is delayed by 15 minutes.
How has the PTC Therapeutics share price performed this year?
Shares in PTC Therapeutics last closed at $48.82 and the price had moved by +47.76% over the past 365 days. In terms of relative price strength the PTC Therapeutics share price has outperformed the S&P500 Index by +27.24% over the past year.
What are the analyst and broker recommendations for PTC Therapeutics?
The overall consensus recommendation for PTC Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PTC Therapeutics dividend yield?
PTC Therapeutics does not currently pay a dividend.
Does PTC Therapeutics pay a dividend?
PTC Therapeutics does not currently pay a dividend.
When does PTC Therapeutics next pay dividends?
PTC Therapeutics does not currently pay a dividend.
How do I buy PTC Therapeutics shares?
To buy shares in PTC Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PTC Therapeutics?
As of the previous close price of $48.82, shares in PTC Therapeutics had a market capitalisation of $3.88bn.
Where are PTC Therapeutics shares listed?
Here are the trading details for PTC Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PTCT
What kind of share is PTC Therapeutics?
Based on an overall assessment of its quality, value and momentum PTC Therapeutics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PTC Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in PTC Therapeutics is $68.33. That is 39.96% above the last closing price of $48.82.
Analysts covering PTC Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $7.77 for the next financial year.
Find out moreWhat is the trend in the PTC Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PTC Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -10.47%.
As of the last closing price of $48.82, shares in PTC Therapeutics were trading +2.29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PTC Therapeutics PE Ratio?
The PTC Therapeutics PE ratio based on its reported earnings over the past 12 months is 40.46. The shares last closed at $48.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PTC Therapeutics?
PTC Therapeutics' management team is headed by:
- Michael Schmertzler - NEC
- Stuart Peltz - CEO
- Emily Hill - CFO
- Neil Almstead - COO
- Matthew Klein - COO
- Mark Boulding - EVP
- Christine Utter - SVP
- Eric Pauwels - OTH
- Allan Jacobson - IND
- Stephanie Okey - IND
- Emma Reeve - IND
- Mary Smith - IND
- David Southwell - IND
- Glenn Steele - IND
- Dawn Svoronos - IND
- Jerome Zeldis - IND